PCOS & Weight Management
Wegovy and PCOS
Quick Answer: Wegovy (semaglutide 2.4 mg) can be an effective weight loss treatment for women with PCOS. PCOS is closely linked to insulin resistance, which Wegovy directly addresses through its GLP-1 mechanism — improving insulin sensitivity, reducing appetite and producing meaningful weight loss that can improve PCOS symptoms including irregular periods, androgen excess and fertility.1 in 10women of reproductive age have PCOS
70–80%of women with PCOS have insulin resistance
~15%average weight loss on Wegovy at 68 weeks
Understanding PCOS
Why PCOS Makes Weight Management So Hard
Weight gain in PCOS is driven by specific hormonal and metabolic mechanisms, not simply lifestyle factors. The central driver is the interplay between insulin resistance and androgen excess — creating a self-perpetuating cycle that makes weight loss physiologically harder than for women without PCOS.
The Insulin-Androgen Vicious Cycle
In women with PCOS, insulin resistance causes the pancreas to produce excess insulin. This compensatory hyperinsulinaemia stimulates the ovaries to produce excess androgens (testosterone). Elevated androgens then contribute to weight gain — particularly visceral abdominal fat — which deepens insulin resistance. Breaking this cycle is the central challenge of PCOS management.
Women with PCOS also have altered secretion and sensitivity to appetite-regulating hormones including leptin and GLP-1. Reduced GLP-1 responsiveness blunts the natural satiety mechanism after meals — making dietary restraint significantly harder than for women without PCOS.
How Wegovy Compares to Other PCOS Treatments
| Treatment | Targets IR | Appetite Suppression | Weight Loss | Menstrual Regularisation |
|---|---|---|---|---|
| Metformin | Yes — moderate | No | Modest (1–3 kg) | Yes — moderate |
| Wegovy (Semaglutide) | Yes — significant | Yes — strong | ~15% body weight | Yes — via weight loss |
| Mounjaro (Tirzepatide) | Yes — greater | Yes — strong | ~20–21% body weight | Yes — via weight loss |
| Lifestyle only | Partial | No | Variable (5–10%) | Variable |
| Combined pill (OCP) | No | No | Minimal | Yes — direct cycle control |
Clinical Mechanisms
How Wegovy Works for PCOS
💊 Improving Insulin Sensitivity
Semaglutide improves insulin sensitivity through both direct and indirect mechanisms. Improved insulin sensitivity reduces the ovarian stimulus for androgen production, breaking the insulin-androgen cycle.
🌡 Restoring Appetite Regulation
For women with PCOS whose appetite regulation is compromised by leptin resistance and reduced GLP-1 responsiveness, semaglutide provides a pharmacological correction — making sustainable dietary behaviour change possible.
🔄 Improving Ovarian Function
Weight loss in PCOS of even 5–10% can restore ovulatory cycles. GLP-1 receptor agonist studies show improvements in menstrual regularity and ovulation rates, with some reporting resumption of regular cycles within 3–6 months.
📊 Evidence Summary
A 2023 systematic review found significant reductions in body weight, BMI, fasting insulin and HOMA-IR in women with PCOS on semaglutide. Improvements in menstrual frequency and androgen markers were also reported.
Important — Contraception and Fertility: Weight loss can restore ovulation in women with PCOS who previously had irregular cycles. If pregnancy is not desired, effective contraception should be used throughout Wegovy treatment. Wegovy is not recommended during pregnancy.
FAQs
Frequently Asked Questions
Yes. Wegovy's GLP-1 mechanism improves insulin sensitivity, reduces appetite and produces meaningful weight loss — all of which can improve PCOS symptoms including irregular periods, androgen excess and fertility. A 2023 systematic review found significant improvements in insulin resistance markers, testosterone levels and menstrual regularity in women with PCOS on semaglutide.
Clinical evidence shows improvements in multiple PCOS symptoms with GLP-1 receptor agonist treatment: reduced testosterone and free androgen index, improved menstrual regularity and ovulation frequency, improvements in hirsutism scores, and reductions in insulin resistance. These improvements are partly direct (insulin-sensitising effect) and partly indirect (via weight loss).
Clinical evidence suggests that GLP-1 receptor agonist treatment — including semaglutide — can improve menstrual regularity and restore ovulation in women with anovulatory PCOS. Some studies report resumption of regular cycles within three to six months of starting treatment, particularly in women who achieve 5–10% weight loss.
Wegovy produces substantially greater weight loss than metformin and provides stronger appetite suppression, which metformin does not offer. For women with PCOS whose primary goal is meaningful weight loss alongside metabolic improvement, Wegovy represents a significantly more potent option. Some patients may benefit from both — this should be discussed with your clinician.
Women with PCOS may find weight loss is somewhat slower or less linear than STEP 1 trial averages in the early months — particularly given the pronounced insulin resistance that characterises PCOS. However, as insulin sensitivity improves and weight decreases, the response typically becomes more consistent. PCOS does not prevent Wegovy from working.
Weight loss in PCOS — even modest amounts of 5–10% of body weight — can restore ovulatory cycles in women with anovulatory PCOS. This is because weight loss reduces visceral fat, improves insulin sensitivity and lowers androgen levels. If pregnancy is desired, discuss timing with your clinician. Use contraception throughout treatment if pregnancy is not desired.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Zheng J et al. J Clin Endocrinol Metab. 2022. NICE TA875. 2023. Wilding JPH et al. STEP 1. N Engl J Med. 2021. Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not medical advice.